MCID: LGH007
MIFTS: 66

Leigh Syndrome malady

Categories: Genetic diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Leigh Syndrome

About this section

Aliases & Descriptions for Leigh Syndrome:

Name: Leigh Syndrome 49 10 45 22 23 47 67
Leigh Disease 10 22 23 12 67 36 65
Leigh's Disease 45 23 46 24
Leigh Syndrome Due to Mitochondrial Complex I Deficiency 49 22 67
Leigh Syndrome Due to Cytochrome C Oxidase Deficiency 49 11 22
Sne 45 22 67
Ls 45 22 67
Leigh Syndrome Due to Mitochondrial Complex Ii Deficiency 67 24
Leigh Syndrome Due to Mitochondrial Complex 1 Deficiency 49 24
Necrotizing Encephalopathy Infantile Subacute of Leigh 45 67
Subacute Necrotizing Encephalomyelopathy 10 23
Leigh Syndrome Due to Mitochondrial Complex Iii Deficiency 67
Necrotizing Encephalopathy, Infantile, Subacute, of Leigh 22
 
Leigh Syndrome Due to Mitochondrial Complex Iv Deficiency 67
Necrotizing Encephalopathy, Infantile Subacute, of Leigh 65
Leigh Syndrome Due to Mitochondrial Complex V Deficiency 67
Leigh Syndrome Due to Mitochondrial Cox4 Deficiency 49
Juvenile Subacute Necrotizing Encephalomyelopathy 10
Encephalopathy, Subacute Necrotizing, Infantile 65
Encephalopathy, Subacute Necrotizing, Juvenile 65
Infantile Subacute Necrotizing Encephalopathy 23
Juvenile Subacute Necrotizing Encephalopathy 23
Infantile Necrotizing Encephalomyelopathy 10
Leigh Syndrome, Due to Cox Deficiency 49
Subacute Necrotizing Encephalopathy 45
Leigh's Necrotizing Encephalopathy 45

Characteristics:



Classifications:



External Ids:

OMIM49 256000
Disease Ontology10 DOID:3652
ICD1027 G31.82
SNOMED-CT59 29570005
MeSH36 D007888
NCIt42 C84814
UMLS65 C0023264, C2931891, C0751267 C0751268, more

Summaries for Leigh Syndrome

About this section
NIH Rare Diseases:45 Leigh syndrome is a rare, inherited neurodegenerative condition. it usually begins in infancy, often after a viral infection. rarely, it begins in the teenage or adult years. signs and symptoms usually progress rapidly and may get worse after a viral infection. early signs may include poor sucking ability; loss of head control and motor skills; loss of appetite; vomiting; and seizures. as the disorder progresses, symptoms may include weakness and lack of muscle tone; spasticity; movement disorders; cerebellar ataxia; and peripheral neuropathy. complications can lead impairment of respiratory, heart and kidney function. leigh syndrome may be caused by changes (mutations) in either mitochondrial dna or nuclear dna:mitochondrial dna-associated leigh syndrome follows a mitochondrial inheritance pattern (also called maternal inheritance) nuclear gene-encoded leigh syndrome may be inherited in an autosomal recessive or x-linked manner, depending on the responsible gene. some people with features very similar to those of leigh syndrome are said to have "leigh-like syndrome." treatment is generally supportive and focuses on the symptoms present. last updated: 2/29/2016

MalaCards based summary: Leigh Syndrome, also known as leigh disease, is related to mitochondrial dna-associated leigh syndrome and narp and leigh syndrome with nephrotic syndrome, and has symptoms including cognitive impairment, abnormality of movement and incoordination. An important gene associated with Leigh Syndrome is NDUFS4 (NADH:Ubiquinone Oxidoreductase Subunit S4), and among its related pathways are Alzheimers disease and Metabolism. Affiliated tissues include kidney, spinal cord and thalamus.

Disease Ontology:10 A mitochondrial metabolism disease characterized by progressive loss of mental and movement abilities. Symptoms usually begin between ages of three months and two years and include loss of appetite, vomiting, irritability and seizure activity.

UniProtKB/Swiss-Prot:67 Leigh syndrome: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.

NINDS:46 Leigh's disease is a rare inherited neurometabolic disorder that affects the central nervous system. This progressive disorder begins in infants between the ages of three months and two years.

Genetics Home Reference:23 Leigh syndrome is a severe neurological disorder that typically arises in the first year of life. This condition is characterized by progressive loss of mental and movement abilities (psychomotor regression) and typically results in death within a couple of years, usually due to respiratory failure. A small number of individuals develop symptoms in adulthood or have symptoms that worsen more slowly.

OMIM:49 Leigh syndrome is an early-onset progressive neurodegenerative disorder with a characteristic neuropathology consisting... (256000) more...

Wikipedia:68 Leigh disease, also known as juvenile subacute necrotizing encephalomyelopathy, Leigh syndrome,... more...

Related Diseases for Leigh Syndrome

About this section

Diseases in the Leigh Syndrome family:

Leigh-Like Syndrome

Diseases related to Leigh Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 190)
idRelated DiseaseScoreTop Affiliating Genes
1mitochondrial dna-associated leigh syndrome and narp34.2BCS1L, COX10, COX15, FOXRED1, NDUFA10, NDUFA12
2leigh syndrome with nephrotic syndrome34.1COX15, FOXRED1, MTFMT, NDUFA10, NDUFA12, NDUFA2
3mitochondrial complex i deficiency31.8FOXRED1, MT-ND3, MT-ND5, NDUFAF2, NDUFAF6, NDUFS3
4mitochondrial complex iv deficiency31.8COX10, COX15, SURF1
5leigh syndrome, french-canadian type12.6
6mitochondrial dna-associated leigh syndrome12.5
7nuclear gene-encoded leigh syndrome12.4
8x-linked leigh syndrome12.3
9leigh syndrome with leukodystrophy12.2
10leigh syndrome with cardiomyopathy12.2
11pyruvate carboxylase deficiency11.5
12congenital lactic acidosis, saguenay-lac-saint-jean type11.4
13lichen sclerosus10.9
14hypokalemic periodic paralysis, type 210.7COX10, COX15, SURF1
15deafness-encephaloneuropathy-obesity-valvulopathy syndrome10.7COX10, COX15, SURF1
16alcoholic cardiomyopathy10.7MT-ATP6, MT-ND5, SDHA
17encephalopathy10.7MT-ND3, MTFMT, SURF1
18gemistocytic astrocytoma10.7COX10, COX15, MT-ATP6, MT-ND3, MT-ND5, NDUFS8
19otof-related deafness10.7NDUFA12, NDUFA2, NDUFAF6, NDUFS7
20plexopathy10.7MT-ATP6, MT-ND5, NDUFS4
21cowden syndrome 210.7SDHA, SDHB
22paragangliomas 510.7SDHA, SDHB
23cribriform carcinoma10.7NDUFS3, NDUFS4
24albinism, oculocutaneous, type iv10.7SDHA, SDHB
25paragangliomas 410.6SDHA, SDHB
26gastrointestinal adenoma10.6NDUFA12, NDUFA2
27thymus basaloid carcinoma10.6FOXRED1, MT-ATP6, MT-ND3, MT-ND5, NDUFAF2, NDUFAF6
28mitochondrial membrane protein-associated neurodegeneration10.6BCS1L, COX10, MT-ATP6, MT-ND3, MT-ND5, NDUFS4
29leptin deficiency10.6NDUFS4, SURF1
30neuroaxonal dystrophy renal tubular acidosis10.6SDHA, SDHB
31paraganglioma and gastric stromal sarcoma10.6SDHA, SDHB
32mitochondrial disorders10.6BCS1L, COX15, FOXRED1, MT-ATP6, MT-ND3, MT-ND5
33cardiofacial syndrome short limbs10.6COX15, SURF1
34mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes10.6BCS1L, COX15, FOXRED1, MT-ATP6, MT-ND3, MT-ND5
35oral hairy leukoplakia10.5SDHA, SDHB
36carnitine palmitoyltransferase i deficiency , muscle10.5SDHA, SDHB
37glycogen storage disease ib10.5SDHA, SDHB
38coenzyme q10 deficiency, primary, 110.4
393-methylglutaconic aciduria with deafness, encephalopathy, and leigh-like syndrome10.4
40male reproductive organ cancer10.4SDHA, SDHB
41denys-drash syndrome10.3
42pseudohermaphroditism10.3
43leigh syndrome10.3BCS1L, COX10, COX15, FOXRED1, MT-ATP6, MT-ND3
44hepatitis10.3
45leukemia10.3
46cysticercosis10.3MT-ND3, MT-ND5
47coenzyme q10 deficiency, primary, 310.3
48mitochondrial complex ii deficiency10.3
49combined oxidative phosphorylation deficiency 1510.3
50coenzyme q10 deficiency, primary, 510.3

Graphical network of the top 20 diseases related to Leigh Syndrome:



Diseases related to leigh syndrome

Symptoms for Leigh Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

256000

Clinical features from OMIM:

256000

HPO human phenotypes related to Leigh Syndrome:

(show all 37)
id Description Frequency HPO Source Accession
1 cognitive impairment hallmark (90%) HP:0100543
2 abnormality of movement hallmark (90%) HP:0100022
3 incoordination hallmark (90%) HP:0002311
4 respiratory insufficiency hallmark (90%) HP:0002093
5 muscular hypotonia hallmark (90%) HP:0001252
6 nystagmus hallmark (90%) HP:0000639
7 strabismus hallmark (90%) HP:0000486
8 seizures typical (50%) HP:0001250
9 optic atrophy typical (50%) HP:0000648
10 ophthalmoparesis typical (50%) HP:0000597
11 cns demyelination HP:0007305
12 lactic acidosis HP:0003128
13 respiratory failure HP:0002878
14 abnormal pattern of respiration HP:0002793
15 increased csf lactate HP:0002490
16 gliosis HP:0002171
17 increased serum lactate HP:0002151
18 failure to thrive HP:0001508
19 hepatocellular necrosis HP:0001404
20 hyperreflexia HP:0001347
21 dystonia HP:0001332
22 global developmental delay HP:0001263
23 dysarthria HP:0001260
24 spasticity HP:0001257
25 muscular hypotonia HP:0001252
26 ataxia HP:0001251
27 seizures HP:0001250
28 intellectual disability HP:0001249
29 hypertrichosis HP:0000998
30 emotional lability HP:0000712
31 optic atrophy HP:0000648
32 nystagmus HP:0000639
33 ophthalmoplegia HP:0000602
34 pigmentary retinopathy HP:0000580
35 ptosis HP:0000508
36 strabismus HP:0000486
37 sensorineural hearing impairment HP:0000407

Drugs & Therapeutics for Leigh Syndrome

About this section

Drugs for Leigh Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 209)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PantoprazoleapprovedPhase 4166102625-70-74679
Synonyms:
102625-70-7
5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole
5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
AC-679
AC1L1IPJ
Astropan
BIDD:GT0003
BRD-A22380646-001-01-5
BSPBio_002320
BY 1023
BY-1023
C11806
C16H15F2N3O4S
CHEBI:519598
CHEBI:7915
CHEMBL1502
CID4679
D05353
DB00213
HMS1922H20
HMS2090H03
HMS2093F14
HSDB 7292
I06-0068
LS-32883
MolPort-003-666-752
MolPort-005-933-577
NCGC00095188-01
NCGC00095188-02
NCGC00095188-03
 
Pantoloc
Pantopan
Pantoprazol
Pantoprazol [INN-Spanish]
Pantoprazole
Pantoprazole (USAN/INN)
Pantoprazole Magnesium
Pantoprazole Na
Pantoprazole Sodium
Pantoprazole Sodium Hydrate
Pantoprazole [USAN:BAN:INN]
Pantoprazole sodium
Pantoprazolum
Pantoprazolum [INN-Latin]
Pantoprozole
Pantor
Pantozol
Protium
Protonix
Protonix I.V.
Protonix IV
SBB070993
SK&F 96022
SK&F-96022
SK-96022
SKF-96022
SPECTRUM1505818
Somac
TL8000127
Tecta
UNII-D8TST4O562
pantoprazole
2
DopamineapprovedPhase 4, Phase 3308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3
Entacaponeapproved, investigationalPhase 447130929-57-65281081
Synonyms:
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
116314-67-1
130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
AC-393
AC1NQY02
BIDD:GT0026
C071192
C07943
C14H15N3O5
CHEBI:4798
CHEMBL953
CID5281081
COM-998
Comtan
Comtan (TN)
Comtess
D00781
 
DB00494
ENTACAPONE
Entacapona
Entacapona [INN-Spanish]
Entacapone
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
HMS2089O16
KB475572
LS-123327
LS-172316
MolPort-003-847-054
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
Novartis brand of entacapone
OR 611
OR-611
Orion brand of entacapone
UNII-4975G9NM6T
entacapone
4
CarbidopaapprovedPhase 415928860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(S)-(-)-Carbidopa hydrate
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa hydrate
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa monohydrate
Carbidopa, (S)-Isomer
 
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
Carbidopum
Carbidopum [INN-Latin]
Carbidopum monohydricum
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-Dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopa hydrate
carbidopum monohydricum
5
LevodopaapprovedPhase 4, Phase 336359-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
6
BudesonideapprovedPhase 438151333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide Inhalation
Budesonide MMX
Budesonide Nasal
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
 
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort FLEXHALER
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Uceris
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
7
NorepinephrineapprovedPhase 459551-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
 
LT03330026
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
8
NaproxenapprovedPhase 424522204-53-11302, 156391
Synonyms:
(+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-(S)-Naproxen
(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionsaeure
(+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]
(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-Naproxen
(+)NAPROXEN
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
(S)-()-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-Naproxen
(S)-2-(6-Methoxy-2-naphthyl)propanoic acid
(S)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-Naproxen
2-(6-Methoxy-2-naphthyl)propionic acid
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI)
22204-53-1
284785_ALDRICH
46482_FLUKA
46482_RIEDEL
65126_FLUKA
AC-1363
AC1L4G3X
AC1Q4ET9
AC1Q4F4H
AC1Q4F4I
ARONIS24306
Acusprain
Aleve
Anaprox
Anax
Anexopen
Apo-Napro-NA
Apo-Naproxen
Apronax
Artagen
Arthrisil
Artrixen
Artroxen
Atiflan
Axer
BIDD:GT0062
BRD-K59197931-001-02-9
BRD-K59197931-236-09-6
BSPBio_002067
Bipronyl
Bonyl
CAS-22204-53-1
CCRIS 5265
CG 3117
CHEBI:7476
CHEMBL154
CID156391
Calosen
Clinosyn
Congex
D-Naproxen
DB08298
DL Naproxen
DL-Naproxen
Danaprox
Daprox
Diocodal
DivK1c_000242
Duk
Dysmenalgit
Dysmenalgit N
EINECS 244-838-7
Ec-Naprosyn
Ec-naprosyn
Equiproxen
Equiproxen (Veterinary)
FT-0082415
Flanax Forte
Flexen
Flexipen
Floginax
Fuxen
Genoxen
HMS1920P13
HMS2089N21
HMS2091H12
HMS500M04
HSDB 3369
Headlon
IDI1_000242
InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
KBio1_000242
KBio2_001457
KBio2_004025
KBio2_006593
KBio3_001567
KBioGR_000597
KBioSS_001457
LS-124738
Laraflex
Lefaine
Leniartil
 
Lopac0_000792
M1021
Methoxypropiocin
MolPort-000-145-960
N8280_SIAL
NAPROXEN
NCGC00016759-01
NCGC00021127-01
NCGC00161591-01
NINDS_000242
NPS
Nafasol
Naixan
Nalyxan
Napflam
Napmel
Naposin
Napratec
Naprelan
Napren
Napren E
Naprius
Naprolag
Naprontag
Naprosin
Naprosyn
Naprosyn LLE
Naprosyn LLE Forte
Naprosyne
Naproxen
Naproxen Kit
Naproxen Sodium
Naproxen [USAN:BAN:INN:JAN]
Naproxen delayed release
Naproxen sodium
Naproxene
Naproxene [INN-French]
Naproxeno
Naproxeno [INN-Spanish]
Naproxenum
Naproxenum [INN-Latin]
Naproxi 250
Naproxi 500
Naproxène
Napxen
Narma
Narocin
Naxen
Naxen F
Naxopren
Naxyn
Naxyn 250
Naxyn 500
Noflam
Novonaprox
Nycopren
Opipramol
Patxen
Prafena
Prestwick0_000791
Prestwick1_000791
Prestwick2_000791
Prestwick_349
Prexan
Priaxen
Pronaxen
Proxen LE
Proxen LLE
RS 3540
RS-3540
Rahsen
Reuxen
Rheumaflex
Roxen
SPBio_000966
SPBio_002861
SPECTRUM1500425
SR-01000075977-3
STOCK1N-50633
Saritilron
Sinartrin
Sinton
Soproxen
Spectrum2_001043
Spectrum3_000514
Spectrum4_000069
Spectrum5_001327
Spectrum_000977
Sutolin
Sutony
TL8003659
Tohexen
Traumox
U-Ritis
UNII-57Y76R9ATQ
UPCMLD-DP001
UPCMLD-DP001:001
Velsay
Veradol
Vinsen
Xenar
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]
d-2-(6-Methoxy-2-naphthyl)propionic acid
d-Naproxen
9
Celecoxibapproved, investigationalPhase 4419169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
10
IbuprofenapprovedPhase 445615687-27-13672
Synonyms:
(+-)-2-(P-Isobutylphenyl)propionic acid
(+-)-Ibuprofen
(+-)-P-Isobutylhydratropic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(4-Isobutylphenyl)-alpha-methylacetic acid
(RS)-ibuprofen
139466-08-3
15687-27-1
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropic acid
58560-75-1
7 Select Childrens Ibuprofen
7 Select Ibuprofen
AC-11312
AC1L1GGE
AC1Q1P84
AC1Q1P85
ACHES-N-PAIN
ARONIS23835
Act-3
Actiprofen
Adex 200
Adran
Advil
Advil (TN)
Advil Liqui-Gels
Advil Liquigels
Advil Migraine
Ak+C2278tren
Alaxan
Algofen
Am-Fam 400
Amelior
Amersol
Amibufen
Anafen
Anco
Andran
Anflagen
Antagil
Antalfene
Antarene
Antiflam
Apo-Ibuprofen
Aprofen REGULAR STRENGTH
Apsifen
Apsifen-F
Artofen
Artril
Artril 300
BB_SC-1358
BIDD:GT0050
BRN 2049713
Babies R Us Ibuprofen
Babies R Us Infants Ibuprofen
Balkaprofen
Being Well Ibuprofen
Betaprofen
Bloom
Bluton
Brofen
Brufanic
Brufen
Brufen 400
Bruflam
Brufort
Buburone
Bufeno
Bufigen
Bukrefen
Bupron
Buracaps
Burana
Butylenin
C01588
C13H18O2
CCRIS 3223
CHEBI:5855
CHEMBL521
CID3672
CPD000058184
Caldolor
Cap-Profen
Care One Ibuprofen
Care One Ibuprofen Ib
Care One Ibuprofen Junior Strength
Care One Ibuprofen childrens
Care One Ibuprofen infants
Careone Ibuprofen Junior Strength
Carol
Cedaprin
Cesra
Children's Advil
Children's Elixsure
Children's Ibuprofen
Children's Motrin
Childrens Advil
Childrens Ibuprofen
Childrens Ibuprofen 100 Dye Free
Childrens Ibuprofen Oral Suspension
Childrens Motrin
Circle K Ibuprofen
Citalgan
Clear Choice Ibuprofen
Cobo
Codral
Combiflam
Conney Ibuprofen
Counteract IB
Cunil
Cvs Pharmacy Ibuprofen
D00126
D007052
DB01050
DOLO PUREN
Daiprophen
Dalsy
Dansida
Deep Relief
Dentigoa
Dg Health Ibuprofen
Dibufen
Dignoflex
Direct Safety Ibuprofen
Dolex
Dolgin
Dolgirid
Dolgit
Dolibu
Dolmaral
Dolo-Dolgit
Dolo-dolgit
Dolocyl
Dolofen
Dolofen-F
Dolofin
Dolofort
Dologel
Dolomax
Doloren
Dolormin
Doltibil
Dolven
Donjust B
Dorival
Dover Addaprin
Drin
Duafen
Duobrus
Dura-Ibu
Duralbuprofen
Dye Free Ibuprofen
Dysdolen
EU-0100691
Easifon
Ebufac
Emflam
Emflam-200
Emodin
Epobron
Eputex
Equaline Childrens Ibuprofen
Equaline Ibuprofen
Equaline Ibuprofen childrens
Equate Ibuprofen
Equate Ibuprofen childrens
Ergix
Esprenit
Exneural
Family Wellness Childrens Ibuprofen
Faspic
Femadon
Femafen
Femapirin
Femidol
Fenbid
Fenbid Spansule
Fendol
Fenspan
Fibraflex
Film Coated Ibuprofen
Formu Care Ibuprofen
Formu Care Ibuprofen childrens
Fulton Street Market Ibuprofen
Gelufene
Gofen
Good Neighbor Pharmacy Childrens Ibuprofen
Good Neighbor Pharmacy Ibuprofen
Good Neighbor Pharmacy Ibuprofen childrens
Good Sense Childrens Ibuprofen Oral Suspension
Good Sense Ibuprofen
Good Sense Ibuprofen Childrens
Good Sense Ibuprofen childrens
Good Sense Ibuprofen infants
Green Guard Ibupro Relief
Green Guard Ibuprofen Relief
Grefen
Gynofug
HMS1920F15
HMS2089P05
HMS2091N03
HMS502M09
HSDB 3099
Haltran
Harmon Face Values Ibuprofen
Health Mart Childrens Ibuprofen
Health Mart Ibuprofen
Health Mart Ibuprofen Ib
Health Sense Infants Ibuprofen Oral Suspension
Health Sense Provil
Healthy Accents Ibuprofen
Healthy Accents Ibuprofen childrens
Healthy Accents Ibuprofen infants
Help I Have An Aching Body
Henry Schein Ibuprofen
I 4883
I01-7039
I0415
I4883_SIGMA
I7905_SIAL
IB-100
IDI1_000887
IP 82
IP-82
IP82
Ibol
Ibren
Ibu
Ibu-Attritin
Ibu-Slo
Ibu-Tab
Ibu-Tab 200
Ibu-attritin
Ibu-slo
Ibu-slow
Ibubest
Ibubeta
Ibucasen
Ibudol
Ibudolor
Ibufen
Ibuflamar
Ibufug
Ibugel
Ibugen
Ibugesic
Ibuhexal
 
Ibulagic
Ibular
Ibulav
Ibuleve
Ibulgan
Ibumed
Ibumerck
Ibumetin
Ibupirac
Ibuprin
Ibuprocin
Ibuprofen
Ibuprofen (NSAID) Pain Releiver/ Fever Reducer
Ibuprofen (nsaid) Pain Reliever/fever Reducer
Ibuprofen 200
Ibuprofen Caplet
Ibuprofen Childrens
Ibuprofen Dye-Free
Ibuprofen IMMEDIATE RELEASE
Ibuprofen Ib
Ibuprofen Immediate release
Ibuprofen Infants
Ibuprofen Junior
Ibuprofen Junior Strength
Ibuprofen Pain Releiver/ Fever Reducer
Ibuprofen Pain Reliever/ Fever Reducer
Ibuprofen Pain Reliever/Fever Reducer
Ibuprofen Pain Reliever/fever Reducer
Ibuprofen Softgels
Ibuprofen childrens
Ibuprofen infants
Ibuprofen junior strength
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprohm
Ibuprophen
Ibusal
Ibutab
Ibutid
Ifen
Inabrin
Infants Advil
Infants Dye-free Ibuprofen
Infants Ibuprofen
Infants Motrin
Inflam
Inoven
Ipren
Irfen
Isodol
Jenaprofen
Junifen
Junior Strength Advil
Junior Strength Ibuprofen
Junior Strength Motrin
KBio1_000887
KBio2_001329
KBio2_003897
KBio2_006465
KBio3_001390
Kesan
Kirkland Signature Ibuprofen
Kirkland Signature Ibuprofen Ib
Kratalgin
LS-7454
Lamidon
Leader Childrens Ibuprofen
Leader Ibuprofen
Leader Ibuprofen 200
Leader Ibuprofen Childrens
Leader Ibuprofen Infants
Lebrufen
Librofem
Lidifen
Lil Drug Store Ibuprofen
Liptan
Lopane
MLS000069733
MLS001146965
Major Childrens Ibuprofen
Malafene
Manypren
Medi-first Ibuprofen
Medi-first Plus Ibuprofen
Medipren
Medique Iprin
Melfen
Mensoton
Midol
Midol 200
Moment
Moore Medical Llc Ibuprofen
Motrin
Motrin (TN)
Motrin IB
Motrin Ib
Motrin Infants
Mynosedin
NCI60_002065
NINDS_000887
NSC 256857
NSC256857
Nagifen-D
Napacetin
Narfen
Neo-Helvagit
Neo-Mindol
NeoProfen
Neobrufen
Neoprofen
Nerofen
Noalgil
Nobafon
Nobfelon
Nobfen
Nobgen
Noritis
Norton
Novadol
Novo-Profen
Novogent
Novogent N
Novoprofen
Nuprilan
Nuprin
Nurofen
Optifen
Opturem
Oralfene
Ostarin
Ostofen
Otis Clapp Ultraprin
Ozonol
P-Isobutylhydratropic Acid
Paduden
Pain Relief
Pain Relief Anti Inflammatory
Pain Relief Ibuprofen
Panafen
Pantrop
Para-Isobutylhydratropic Acid
Paxofen
Pedia-Profen
PediaProfen
Pediacare Childrens
Pediacare Infants
Pediaprofen
Pediatric Advil
Perofen
Perrigo Ibuprofen
Physicianscare Ibuprofen
Preferred Plus Ibuprofen
Preferred Plus Ibuprofen 200
Proartinal
Probufen
Profen
Profen Ib
Profen Ib childrens
Profen Ib infants
Proflex
Proprinal
Provon
Quadrax
Quality Choice Ibuprofen 200
R.D. 13621
RD 13621
Rafen
Ranofen
Rebugen
Relcofen
Rexall Ibuprofen
Rhinadvil
Rofen
Roidenin
Rufen
Rufin
Rupan
Rx Act Ibuprofen
Rx Act Ibuprofen childrens
SAM002264619
SMR000058184
SPBio_000178
STK177358
Sadefen
Salivia
Salprofen
Seclodin
Sednafen
Seklodin
Seskafen
Shoprite Childrens Ibuprofen
Shoprite Ibuprofen
Shoprite Ibuprofen Ib
Shoprite Ibuprophen
Shoprite Infants Ibuprofen
Simply Right Ibuprofen
Siyafen
Smart Sense Ibuprofen
Smart Sense Ibuprofen gluten free
Smart Sense Ibuprofen infants
Solpaflex
Solufen
Stelar
Sugafen
Sunmark Ibuprofen
Sunmark Ibuprofen Ib
Sunmark Ibuprofen childrens
Sunmark Ibuprofen infants
Suprafen
Suspren
Syntofene
TL8001184
Tab-Profen
Tabalon
Tabalon 400
Tatanal
Tempil
Tofen
Togal N
Tonal
Topcare Childrens Ibuprofen
Topcare Ibuprofen
Topcare Ibuprofen Junior Strength
Topcare Ibuprofen childrens
Topcare Infants Ibuprofen
Trendar
U 18573
U-18,573
U-18573
UCB 79171
Unipron
Upfen
Uprofen
Urem
VUFB 9649
Welby Health Ibuprofen
Zafen
Zofen
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(P-Isobutylphenyl)propionic acid
alpha-p-Isobutylphenylpropionate
alpha-p-Isobutylphenylpropionic acid
ibuprofen
p-Isobutyl-2-phenylpropionate
p-Isobutyl-2-phenylpropionic acid
p-Isobutylhydratropate
p-Isobutylhydratropic acid
11
Calcium carbonateapprovedPhase 4, Phase 1194
Synonyms:
7 Select Antacid
Alka-seltzer Fruit Chews
Alka-seltzer Heartburn Reliefchews
Alka-seltzer Heartburn Reliefchews Cool Mint
Alka-seltzer Heartburn Reliefchews Strawberry
Antacid
Antacid Extra Strength Assorted Berries
Antacid Ultra Strength
Antacid Ultra Strength Assorted Berries
Antacid extra strength
Antacid maximum strength ultra
Being Well Antacid
CaCO3
Calcid ANTACID CALCIUM SUPPLEMENT REGULAR STRENGTH
Calcium Antacid
Calcium Antacid extra strength
Calcium Carbonate
Calcium Carbonate (Antacid)
Calcium Carbonate Chewable Antacid
Calcium Carbonate Extra Strength Antacid
Calcium carbonate
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
Carbonato de calcio
Carbonic acid calcium salt (1:1)
Care One Calcium Antacid
Childrens Chewable Antacid
Childrens Pepto
Childrens Stomach Relief
Chooz
D-cal
D-cal Kids
Dg Health Antacid Calcium Supplement
Dg Health Antacid Calcium Supplement regular strength
Dg Health Calcium Antacid
Dg Health Calcium Antacid extra strength
Equaline Antacid
Equaline Antacid regular strength
Equate Antacid
Equate Antacid regular strength
Exchange Select Calcium Antacid
Extra Strength
Extra Strength antacid calcium supplement
First Aid Shot Therapy Upset Stomach Relief
Formu Care Calcium Antacid
Good Sense Antacid
Green Guard Stomach Relief
Health Mart Calcium Antacid
Health Mart Calcium Antacid Assorted Fruit
 
Healthmart Calcium Antacid
Healthy Accents Antacid
Healthy Accents Antacid extra strength
Healthy Mama TAME THE FLAME
Heartburn Relief To Go
His Ulc Mint Blue
Kalziumkarbonat
Kirkland Signature Antacid
Kohlensaurer kalk
Leader Antacid
Leader Antacid Regular Strength
Maximum Strength
Medi First Antacid
Medi First Plus Antacid
Medi-first Antacid
Medi-first Plus Antacid
Medique Alcalak
Medique Ban-acid Maximum Strength 750
Meijer Softchews
Miralac
Miralac Antacid
Moore Medical Antacid
Nutralox
Physicianscare Antacid
Plus Pharma Calcium Antacid
Precipitated calcium carbonate
Regular Strength
Regular Strength Antacid Calcium Supplement
Rexall Antacid
Rx Act Antacid extra strength
Select Brand Antacid Assorted Berries
Sunmark Assorted Berries
Sunmark Calcium Antacid
Sunmark Calcium Antacid REGULAR STRENGTH
Sunmark Calcium Antacid extra strength
Sunmark Calcium Antacid regular strength
Sunmark Smooth Antacid
Titralac
Topcare Antacid Calcium
Topcare Antacid Calcium Extra Strength
Topcare Antacid Calcium Regular Strength
Topcare Antacid Calcium Ultra Strength
Trial Antacid
Tums
Tums Chewy Delights
Tums EX
Tums Smoothies
Tums ULTRA
Tums freshers
Ultrastrength
Welby Health Antacid
e 170
12
OseltamivirapprovedPhase 4, Phase 193204255-11-865028
Synonyms:
(-)-Oseltamivir
(-)-oseltamivir
(3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid
(−)-oseltamivir
196618-13-0
204255-11-8
4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
AC1L22FK
AC1Q63H0
Agucort
Agucort (TN)
BIDD:GT0426
BRD-K76011241-045-01-5
C08092
CHEBI:7798
CHEMBL1229
CID65028
D08306
DB00198
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate
FT-0082384
 
GS 4104
GS-4104
GS4104
HMS2090C11
HSDB 7433
LS-57422
MolPort-005-933-026
NCGC00178698-01
Oseltamivir
Oseltamivir (INN)
Oseltamivir [INN:BAN]
Oseltamivir phosphate
Oseltamivirum
Ro-64-0796
Ro-640796
Tamiflu
Tamiflu (*Phosphate salt 1:1*)
Tamiflu-Free
Tamvir
UNII-20O93L6F9H
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
oseltamivir
oseltamivirum
13Analgesics, Non-NarcoticPhase 4, Phase 35184
14Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 15501
15
SerotoninPhase 4, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
16Catechol O-Methyltransferase InhibitorsPhase 483
17Neurotransmitter Uptake InhibitorsPhase 4, Phase 22857
18AnalgesicsPhase 4, Phase 39358
19Antidepressive AgentsPhase 4, Phase 22367
20Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 33549
21Cyclooxygenase InhibitorsPhase 4, Phase 32225
22AntacidsPhase 4, Phase 31453
23Contraceptives, OralPhase 4, Phase 2, Phase 1, Phase 03734
24Antiparkinson AgentsPhase 4, Phase 21312
25Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 18071
26Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 117220
27Respiratory System AgentsPhase 4, Phase 2, Phase 33931
28Aromatic Amino Acid Decarboxylase InhibitorsPhase 4116
29Antirheumatic AgentsPhase 4, Phase 38496
30Calcium, DietaryPhase 4, Phase 3, Phase 14678
31Adrenergic AgonistsPhase 42331
32Adrenergic beta-2 Receptor AgonistsPhase 4741
33Adrenergic beta-AgonistsPhase 41266
34Anti-Asthmatic AgentsPhase 4, Phase 2, Phase 32796
35Adrenergic AgentsPhase 4, Phase 24204
36Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
37Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 118510
38Anti-Ulcer AgentsPhase 4, Phase 31453
39Gastrointestinal AgentsPhase 4, Phase 3, Phase 16401
40Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 18478
41
Proton pump inhibitorsPhase 4, Phase 3958
Synonyms:
 
PPIs
42glucocorticoidsPhase 4, Phase 13896
43HormonesPhase 4, Phase 2, Phase 111748
44Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 19988
45Formoterol FumaratePhase 4385
46Hormone AntagonistsPhase 4, Phase 2, Phase 110002
47Bronchodilator AgentsPhase 4, Phase 22377
48Dopamine AgentsPhase 4, Phase 33084
49Serotonin and Noradrenaline Reuptake InhibitorsPhase 4391
50Duloxetine HydrochloridePhase 4258

Interventional clinical trials:

(show top 50)    (show all 116)
idNameStatusNCT IDPhase
1Stalevo in Early Wearing-Off PatientsCompletedNCT00125567Phase 4
2Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)CompletedNCT00261339Phase 4
3Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With AsthmaCompletedNCT02062463Phase 4
4Longitudinal Surveillance Registry (LSR) of ACUITY SpiralRecruitingNCT00955708Phase 4
5The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive ImpairmentRecruitingNCT02590874Phase 4
6Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenActive, not recruitingNCT00346216Phase 4
7A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With InfluenzaNot yet recruitingNCT02561169Phase 4
8Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.CompletedNCT00150449Phase 3
9Evaluation of the Active Living Every Day Exercise Program for People With ArthritisCompletedNCT00146367Phase 2, Phase 3
10Health Benefits of an Exercise Program for Adults With ArthritisCompletedNCT00146393Phase 2, Phase 3
11Evaluation of Walk With Ease in ArthritisCompletedNCT00526435Phase 3
12A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 MonthsCompletedNCT01000311Phase 3
13Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsCompletedNCT00241553Phase 3
14Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsCompletedNCT00241527Phase 3
15Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and DyslipidaemiaCompletedNCT00330785Phase 3
16RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in DiabetesCompletedNCT00379769Phase 3
17Does Tension-Free Herniorrhaphy or Laparoscopic Herniorrhaphy Achieve Equal or Better Recurrence Rates and Lower Costs While Achieving Equivalent Outcomes for Hernia Patients?CompletedNCT00032448Phase 3
18National Multiple Sclerosis Society (NMSS) Pilot Study of Transcranial Direct Current Stimulation (tDCS)RecruitingNCT02746705Phase 3
19MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerRecruitingNCT01805076Phase 3
20Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With ChemotherapyRecruitingNCT01901094Phase 3
21An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseaseRecruitingNCT02542696Phase 3
22A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseaseRecruitingNCT02469090Phase 3
23Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFERecruitingNCT02630316Phase 2, Phase 3
24Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)RecruitingNCT02576574Phase 3
25Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic BronchitisRecruitingNCT02049294Phase 2, Phase 3
26Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)RecruitingNCT02625623Phase 3
27"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"RecruitingNCT02348619Phase 3
28A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) (the EVOLVE-MS Study)RecruitingNCT02634307Phase 3
29Preoperative Intravenous Iron to Treat Anaemia in Major SurgeryRecruitingNCT01692418Phase 3
30Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsRecruitingNCT02687451Phase 3
31Weight Loss and Exercise for Communities With Arthritis in North CarolinaRecruitingNCT02577549Phase 3
32Beraprost-314d Added-on to Tyvaso® (BEAT)RecruitingNCT01908699Phase 3
33Pancreas Resection With and Without DrainsRecruitingNCT01441492Phase 3
34Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular LensRecruitingNCT02487160Phase 2, Phase 3
35A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular DiseaseActive, not recruitingNCT00501059Phase 3
36A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).Active, not recruitingNCT02222493Phase 3
37Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial DiseaseEnrolling by invitationNCT02023866Phase 2, Phase 3
38Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E TreatmentTerminatedNCT00220831Phase 2, Phase 3
39Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)TerminatedNCT00211224Phase 3
40Safety and Efficacy Study of EPI-743 in Children With Leigh SyndromeCompletedNCT01721733Phase 2
41Atomoxetine and Huntington's DiseaseCompletedNCT00368849Phase 2
42Citalopram to Enhance Cognition in HDCompletedNCT00271596Phase 2
43A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedNCT01500200Phase 2
44ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDCompletedNCT01381107Phase 1, Phase 2
45A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01240915Phase 2
46DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial CarcinomaCompletedNCT01353222Phase 2
47A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00694941Phase 2
48Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower ExtremitiesCompletedNCT00493051Phase 2
49Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIVCompletedNCT00122486Phase 2
50The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic RhinosinusitisRecruitingNCT02403479Phase 1, Phase 2

Search NIH Clinical Center for Leigh Syndrome


Cochrane evidence based reviews: leigh disease

Genetic Tests for Leigh Syndrome

About this section

Genetic tests related to Leigh Syndrome:

id Genetic test Affiliating Genes
1 Leigh Syndrome (nuclear Dna Mutation)22 BCS1L, COX10, DLD, MTFMT, NDUFA1, NDUFA10, NDUFAF2, NDUFAF6, NDUFS1, NDUFS3 (show all 19)

NDUFS4, NDUFS7, NDUFS8, NDUFV1, SCO1, SCO2, SDHA, SURF1, FOXRED1

2 Leigh Syndrome Due to Mitochondrial Complex I Deficiency22 NDUFA2
3 Leigh Syndrome (mtdna Deletion)22
4 Leigh Syndrome (mtdna Mutation)22

Anatomical Context for Leigh Syndrome

About this section

MalaCards organs/tissues related to Leigh Syndrome:

33
Kidney, Spinal cord, Thalamus, Cerebellum, Heart, Eye, Lung

Animal Models for Leigh Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Leigh Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes

Publications for Leigh Syndrome

About this section

Articles related to Leigh Syndrome:

(show top 50)    (show all 156)
idTitleAuthorsYear
1
Aberrant membranous expression of I^-catenin predicts poor prognosis in patients with craniopharyngioma. (26547438)
2015
2
A rare case of cleidocranial dysplasia presenting with failure to thrive. (25810671)
2015
3
Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. (25657025)
2015
4
The Protective Effects of IGF-1 on Different Subpopulations of DRG Neurons with Neurotoxicity Induced by gp120 and Dideoxycytidine In Vitro. (25489421)
2014
5
A correlative study of polymorphisms of CYP2C19 and MDR1 C3435T with the pharmacokinetic profiles of lansoprazole and its main metabolites following single oral administration in healthy adult Chinese subjects. (24022708)
2014
6
PDCD5 expression predicts a favorable outcome in patients with hepatocellular carcinoma. (23807738)
2013
7
Epstein-Barr Virus Infection Induces Aberrant TLR Activation Pathway and Fibroblast-Myofibroblast Conversion in Scleroderma. (24129067)
2013
8
Alterations in gene expression in mutant amyloid precursor protein transgenic mice lacking Niemann-Pick type C1 protein. (23382922)
2013
9
Capillary hemangioma masquerading as a renal artery pseudoaneurysm. (22342407)
2012
10
Kaposi's sarcoma in pregnancy after initiation of highly active antiretroviral therapy: a manifestation of immune reconstitution syndrome. (23258835)
2012
11
Cutaneous Mycobacterium kansasii infection in a patient with AIDS post initiation of antiretroviral therapy. (21795826)
2011
12
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. (20832730)
2010
13
Functional diversity of Robo receptor immunoglobulin domains promotes distinct axon guidance decisions. (20206526)
2010
14
Visiting a sauna: does inhaling hot dry air reduce common cold symptoms? A randomised controlled trial. (21143077)
2010
15
Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. (20196086)
2010
16
Immunologic behavior of human cysteine-rich secretory protein 1 (hCRISP1) in primates: prospects for immunocontraception. (20226442)
2010
17
Influence of PAHs exposure and GSTT1, GSTM1 genotypes on urinary 1-OHP as exposure biomarker]. (19548560)
2009
18
Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. (19635926)
2009
19
Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease. (18483151)
2008
20
ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. (18432406)
2008
21
Colonic anion secretory defects and metabolic acidosis in mice lacking the NBC1 Na+/HCO3- cotransporter. (17192275)
2007
22
A sticky case of intestinal obstruction. (17245592)
2007
23
SWI/SNF binding to the HO promoter requires histone acetylation and stimulates TATA-binding protein recruitment. (16705163)
2006
24
Measurement of two caspase activities simultaneously in living cells by a novel dual FRET fluorescent indicator probe. (16683263)
2006
25
Determinants of autonomic dysfunction in idiopathic Parkinson's disease. (16362830)
2005
26
Poly(ADP-ribose) polymerases: managing genome stability. (15743666)
2005
27
Circadian and seasonal variation of first febrile seizures. (15580213)
2004
28
Caspase 8 small interfering RNA prevents acute liver failure in mice. (12810955)
2003
29
Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. (14660054)
2002
30
Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. (11686223)
2001
31
MR imaging of shaken baby syndrome manifested as chronic subdural hematoma. (11752989)
2001
32
A tomato homologue of the human protein PIRIN is induced during programmed cell death. (11485202)
2001
33
Vertigo and amaurosis fugax secondary to Takayasu's arteritis. (11459913)
2001
34
Activation of G protein by opioid receptors: role of receptor number and G-protein concentration. (10822058)
2000
35
A long-standing dermal nodule on the neck of a young woman. Diagnosis: bronchogenic cyst. (10890996)
2000
36
Pseudotumor cerebri manifesting as a symptom of acute promyelocytic leukemia. (10703247)
2000
37
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. (9926921)
1999
38
The interacting RNA polymerase II subunits, hRPB11 and hRPB3, are coordinately expressed in adult human tissues and down-regulated by doxorubicin. (9607318)
1998
39
Effects of estradiol-17 beta and hCG supplementation on superovulatory responses and embryo quality in swamp buffalo (Bubalus bubalis) implanted with norgestomet. (9329859)
1997
40
Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. (8770940)
1996
41
Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. (8660101)
1996
42
The treatment of deep vein thrombosis with continuous intravenous low-molecular-weight dermatan sulphate (Desmin). A pilot study. (8987160)
1996
43
Colocalization of the genes coding for the alpha 3 and beta 3 subunits of soluble guanylyl cyclase to human chromosome 4 at q31.3-q33. (8097486)
1993
44
Radioimmunoimaging of subacute infective endocarditis using a technetium-99m monoclonal granulocyte-specific antibody. (1778210)
1991
45
Finnish type of familial amyloidosis: cosegregation of Asp187----Asn mutation of gelsolin with the disease in three large families. (1652889)
1991
46
Ossifying fibromyxoid tumor. (2123607)
1990
47
Urethral stricture disease in children. (7299929)
1981
48
Clinical and diagnostic problems in posterior fossa tumors in children (analysis of 100 cases). (1031887)
1976
49
Flagyl (Metronidazole) in the treatment of intestinal amebiasis. 3. (5031394)
1972
50
Otorhinophyma, pruritus and alopecia totalis syndrome; response to testosterone. (20262878)
1947

Variations for Leigh Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leigh Syndrome:

67 (show all 29)
id Symbol AA change Variation ID SNP ID
1COX15p.Arg217TrpVAR_019596rs28939711
2COX15p.Ser344ProVAR_033117
3MT-ATP6p.Leu156ArgVAR_000793
4MT-ATP6p.Leu156ProVAR_000794
5MT-ATP6p.Leu217ProVAR_000797
6MT-ATP6p.Leu220ProVAR_073700
7MT-ND3p.Ala47ThrVAR_035092
8MT-ND5p.Phe124LeuVAR_035424
9MT-ND5p.Ser250CysVAR_035429
10NARS2p.Asn381SerVAR_073724
11NDUFAF5p.Leu159PheVAR_067956
12NDUFS8p.Pro79LeuVAR_019538rs28939679
13NDUFS8p.Arg102HisVAR_019539
14NDUFV1p.Thr423MetVAR_008847
15POLGp.Gly848SerVAR_023675
16POLGp.Arg232HisVAR_058871
17SDHAp.Arg554TrpVAR_002449
18SDHAp.Ala524ValVAR_016878
19SDHAp.Cys189GlyVAR_074022
20SURF1p.Gly124GluVAR_007450rs28933402
21SURF1p.Ile246ThrVAR_007452
22SURF1p.Gly124ArgVAR_015258
23SURF1p.Tyr274AspVAR_015259
24SURF1p.Leu90ProVAR_068649
25SURF1p.Val177GlyVAR_068650
26SURF1p.Gly205GluVAR_068651
27SURF1p.Met235ThrVAR_068652
28SURF1p.Ala248AspVAR_068653
29SURF1p.Gly257ArgVAR_068654

Clinvar genetic disease variations for Leigh Syndrome:

5 (show all 47)
id Gene Variation Type Significance SNP ID Assembly Location
1MT-ND1NC_012920.1: m.3481G> Asingle nucleotide variantPathogenicrs587776433GRCh37Chr MT, 3481: 3481
2MT-ND1NC_012920.1: m.3890G> Asingle nucleotide variantPathogenicrs587776434GRCh37Chr MT, 3890: 3890
3MT-TWNC_012920.1: m.5523T> Gsingle nucleotide variantPathogenicrs587776435GRCh37Chr MT, 5523: 5523
4MT-TWNC_012920.1: m.5559A> Gsingle nucleotide variantPathogenicrs370471013GRCh37Chr MT, 5559: 5559
5MT-CO3NC_012920.1: m.9478T> Csingle nucleotide variantPathogenicrs587776437GRCh37Chr MT, 9478: 9478
6MT-ND3NC_012920.1: m.10254G> Asingle nucleotide variantPathogenicrs587776438GRCh38Chr MT, 10254: 10254
7MT-ND4NC_012920.1: m.11984T> Csingle nucleotide variantPathogenicrs200911567GRCh37Chr MT, 11984: 11984
8MT-ND5NC_012920.1: m.13514A> Gsingle nucleotide variantPathogenicrs587776440GRCh37Chr MT, 13514: 13514
9MT-TVNC_012920.1: m.1644G> Tsingle nucleotide variantPathogenicrs587776441GRCh37Chr MT, 1644: 1644
10MT-ND1NC_012920.1: m.3928G> Csingle nucleotide variantPathogenicrs587776442GRCh37Chr MT, 3928: 3928
11MT-ATP6NC_012920.1: m.8839G> Csingle nucleotide variantPathogenicrs369202065GRCh37Chr MT, 8839: 8839
12MT-ATP6NC_012920.1: m.8989G> Csingle nucleotide variantPathogenicrs587776444GRCh37Chr MT, 8989: 8989
13undetermined variantPathogenic
14MT-ND3NC_012920.1: m.10134C> Asingle nucleotide variantPathogenicrs587780529GRCh37Chr MT, 10134: 10134
15ECHS1NM_004092.3(ECHS1): c.2T> G (p.Met1Arg)single nucleotide variantLikely pathogenic, Pathogenicrs587776497GRCh38Chr 10, 133373332: 133373332
16ECHS1NM_004092.3(ECHS1): c.5C> T (p.Ala2Val)single nucleotide variantLikely pathogenic, Pathogenicrs587776498GRCh37Chr 10, 135186833: 135186833
17IARS2NM_018060.3(IARS2): c.1821G> A (p.Trp607Ter)single nucleotide variantPathogenicrs373436822GRCh38Chr 1, 220126827: 220126827
18IARS2NM_018060.3(IARS2): c.2122G> A (p.Glu708Lys)single nucleotide variantPathogenicrs143722284GRCh37Chr 1, 220311332: 220311332
19NDUFS8NM_002496.3(NDUFS8): c.343A> G (p.Lys115Glu)single nucleotide variantLikely pathogenicrs764276946GRCh38Chr 11, 68033254: 68033254
20SURF1NM_003172.3(SURF1): c.106+1G> Csingle nucleotide variantLikely pathogenicrs863224926GRCh37Chr 9, 136223123: 136223123
21MTFMTNM_139242.3(MTFMT): c.626C> T (p.Ser209Leu)single nucleotide variantPathogenicrs201431517GRCh37Chr 15, 65313871: 65313871
22MT-ATP6m.9191T> Csingle nucleotide variantPathogenicrs386829069GRCh37Chr MT, 9191: 9191
23NDUFS4NM_002495.3(NDUFS4): c.462delA (p.Lys154Asnfs)deletionPathogenicrs587776949GRCh38Chr 5, 53683155: 53683155
24MT-TVm.1624C> Tsingle nucleotide variantPathogenicrs199476144GRCh37Chr MT, 1624: 1624
25MT-TWm.5537_5538insTinsertionPathogenicrs199474672GRCh37Chr MT, 5537: 5538
26MT-TKm.8344A> Gsingle nucleotide variantPathogenicrs118192098GRCh37Chr MT, 8344: 8344
27MT-TKm.8363G> Asingle nucleotide variantPathogenicrs118192100GRCh37Chr MT, 8363: 8363
28MT-TL1m.3243A> Gsingle nucleotide variantPathogenicrs199474657GRCh37Chr MT, 3243: 3243
29MT-ATP6m.8993T> Gsingle nucleotide variantPathogenicrs199476133GRCh37Chr MT, 8993: 8993
30MT-ATP6m.8993T> Csingle nucleotide variantPathogenicrs199476133GRCh37Chr MT, 8993: 8993
31MT-ATP6m.9176T> Csingle nucleotide variantPathogenicrs199476135GRCh37Chr MT, 9176: 9176
32MT-ATP6m.8851T> Csingle nucleotide variantPathogenicrs199476136GRCh37Chr MT, 8851: 8851
33MT-ATP6m.9185T> Csingle nucleotide variantPathogenicrs199476138GRCh37Chr MT, 9185: 9185
34MT-ATP6m.9176T> Gsingle nucleotide variantPathogenicrs199476135GRCh37Chr MT, 9176: 9176
35MT-CO3m.9537dupCduplicationPathogenicrs267606614GRCh37Chr MT, 9537: 9537
36MT-ND6NC_012920.1: m.14484T> Csingle nucleotide variantPathogenicrs199476104GRCh37Chr MT, 14484: 14484
37MT-ND6m.14459G> Asingle nucleotide variantPathogenicrs199476105GRCh37Chr MT, 14459: 14459
38MT-ND6m.14487T> Csingle nucleotide variantPathogenicrs199476109GRCh37Chr MT, 14487: 14487
39MT-ND5m.12706T> Csingle nucleotide variantPathogenicrs267606893GRCh37Chr MT, 12706: 12706
40MT-ND5m.13513G> Asingle nucleotide variantPathogenicrs267606897GRCh37Chr MT, 13513: 13513
41MT-ND5m.13042G> Asingle nucleotide variantPathogenicrs267606898GRCh37Chr MT, 13042: 13042
42MT-ND4m.11777C> Asingle nucleotide variantPathogenicrs28384199GRCh37Chr MT, 11777: 11777
43MT-ND3m.10191T> Csingle nucleotide variantPathogenicrs267606890GRCh37Chr MT, 10191: 10191
44MT-ND3m.10158T> Csingle nucleotide variantPathogenicrs199476117GRCh37Chr MT, 10158: 10158
45MT-ND3m.10197G> Asingle nucleotide variantPathogenicrs267606891GRCh37Chr MT, 10197: 10197
46MT-ND2m.4681T> Csingle nucleotide variantPathogenicrs267606889GRCh37Chr MT, 4681: 4681
47MT-ND1m.3460G> Asingle nucleotide variantPathogenicrs199476118GRCh37Chr MT, 3460: 3460

Expression for genes affiliated with Leigh Syndrome

About this section
Search GEO for disease gene expression data for Leigh Syndrome.

Pathways for genes affiliated with Leigh Syndrome

About this section

GO Terms for genes affiliated with Leigh Syndrome

About this section

Cellular components related to Leigh Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytochrome complexGO:007006910.4COX10, COX15

Biological processes related to Leigh Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1succinate metabolic processGO:000610511.0SDHA, SDHB
2heme a biosynthetic processGO:000678410.9COX10, COX15
3biosynthetic processGO:000905810.8MTFMT, NDUFAF6
4respiratory chain complex IV assemblyGO:000853510.8COX15, SURF1
5heme biosynthetic processGO:000678310.8COX10, COX15
6mitochondrial electron transport, NADH to ubiquinoneGO:000612010.7MT-ND3, MT-ND5, NDUFA10, NDUFA12, NDUFS3, NDUFS4
7hydrogen ion transmembrane transportGO:190260010.7COX10, COX15
8respiratory electron transport chainGO:002290410.6MT-ND3, NDUFA12, NDUFAF2, NDUFS4
9porphyrin-containing compound metabolic processGO:000677810.6COX10, COX15
10oxidation-reduction processGO:005511410.3MT-ND3, MT-ND5, NDUFA12, NDUFS3, NDUFS7, NDUFS8
11cellular metabolic processGO:004423710.3NDUFS3, NDUFS4, NDUFS8

Molecular functions related to Leigh Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1succinate dehydrogenase (ubiquinone) activityGO:000817710.7SDHA, SDHB
2electron carrier activityGO:000905510.4NDUFS3, SDHB
3NADH dehydrogenase (ubiquinone) activityGO:000813710.3NDUFA12, NDUFAF2, NDUFS3, NDUFS7, NDUFS8
44 iron, 4 sulfur cluster bindingGO:005153910.1NDUFS7, NDUFS8

Sources for Leigh Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet